Randomized, placebo-controlled phase II trial of heat-killed Mycobacterium vaccae (Longcom batch) formulated as an oral pill (V7)

Human Vaccines and Immunotherapeutics

Volumn 9, Issue 9, 2013, Pages 1852-1856

  Efremenko, Yuri V ^a   Butov, Dmytro A ^b   Prihoda, Natalia D ^a   Zaitzeva, Svetlana I ^b   Yurchenko, Larisa V ^a   Sokolenko, Nina I ^a   Butova, Tetyana S ^b   Stepanenko, Anna L ^b   Kutsyna, Galyna A ^c   Jirathitikal, Vichai ^d   Bourinbaiar, Aldar S ^d  

^a Lisichansk Regional Tuberculosis Dispensary ^*  (Ukraine)

^b KHARKIV NATIONAL MEDICAL UNIVERSITY   (Ukraine)

^c Lugansk State Medical University   (Ukraine)

^d Immunitor Inc   (Canada)

Author keywords

DOT; Drug resistant TB; Imm02; Immunomodulator; Inflammation; Mucosa; Mycobacterium tuberculosis; NCT01380119; Therapeutic vaccine

Indexed keywords

HEMOGLOBIN; MYCOBACTERIUM VACCINE; PLACEBO; UNCLASSIFIED DRUG; VACCAE;

ABSENCE OF SIDE EFFECTS; ADULT; ARTICLE; AXILLA TEMPERATURE; BACTERIAL CLEARANCE; BODY MASS; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; HEMOGLOBIN DETERMINATION; HUMAN; LEUKOCYTE COUNT; LUNG TUBERCULOSIS; LYMPHOCYTE COUNT; MALE; MYCOBACTERIUM VACCAE; PHASE 2 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; SPUTUM SMEAR; TREATMENT OUTCOME; WEIGHT GAIN;

DOT; DRUG-RESISTANT TB; IMM02; IMMUNOMODULATOR; INFLAMMATION; MUCOSA; MYCOBACTERIUM TUBERCULOSIS; NCT01380119; THERAPEUTIC VACCINE;

ADMINISTRATION, ORAL; ADULT; ANTITUBERCULAR AGENTS; FEMALE; HUMANS; IMMUNOTHERAPY; MALE; MIDDLE AGED; MYCOBACTERIUM; PLACEBOS; SPUTUM; TREATMENT OUTCOME; TUBERCULOSIS VACCINES; TUBERCULOSIS, PULMONARY; VACCINES, INACTIVATED;

EID: 84884647588     PISSN: 21645515     EISSN: 2164554X     Source Type: Journal    
DOI: 10.4161/hv.25280     Document Type: Article

References (27)

1. Lienhardt C, Vernon A, Raviglione MC. New drugs and new regimens for the treatment of tuberculosis: review of the drug development pipeline and implications for national programmes. Curr Opin Pulm Med 2010; 16:186-93; PMID:20216421
2. Churchyard GJ, Kaplan G, Fallows D, Wallis RS, Onyebujoh P, Rook GA. Advances in immunotherapy for tuberculosis treatment. Clin Chest Med 2009; 30:769-82, ix; PMID:19925966; http://dx.doi.org/10.1016/j.ccm.2009.08.009
3. Dheda K, Schwander SK, Zhu B, van Zyl-Smit RN, Zhang Y. The immunology of tuberculosis: from bench to bedside. Respirology 2010; 15:433-50; PMID:20415982; http://dx.doi.org/10.1111/j.1440-1843.2010.01739.x
4. Doherty TM. Immunotherapy for TB. Immunotherapy 2012; 4:629-47; PMID:22788130; http://dx.doi.org/10.2217/imt.12.52
5. Prabowo SA, Gröschel MI, Schmidt EDL, Skrahina A, Mihaescu T, Hastürk S, et al. Targeting multidrugresistant tuberculosis (MDR-TB) by therapeutic vaccines. Med Microbiol Immunol 2013; 202:95-104; PMID:23143437; http://dx.doi.org/10.1007/s00430-012-0278-6
6. Stanford J, Stanford C, Grange J. Immunotherapy with Mycobacterium vaccae in the treatment of tuberculosis. Front Biosci 2004; 9:1701-19; PMID:14977580; http://dx.doi.org/10.2741/1292
7. Boenickse R, Juhasz E. Beschreibung der neuen species Mycobacterium vaccae n.sp. Zentralbl Bakteriol Orig 1964; 192:133-5; PMID:14176844
8. von Reyn CF, Mtei L, Arbeit RD, Waddell R, Cole B, Mackenzie T, et al.; DarDar Study Group. Prevention of tuberculosis in Bacille Calmette- Guérin-primed, HIV-infected adults boosted with an inactivated whole-cell mycobacterial vaccine. AIDS 2010; 24:675-85; PMID:20118767; http://dx.doi.org/10.1097/QAD.0b013e3283350f1b
9. Dalgleish AG. Therapeutic cancer vaccines: why so few randomised phase III studies reflect the initial optimism of phase II studies. Vaccine 2011; 29:8501-5; PMID:21933695; http://dx.doi.org/10.1016/j.vaccine.2011.09.012
10. Hale MW, Rook GA, Lowry CA. Pathways underlying afferent signaling of bronchopulmonary immune activation to the central nervous system. Chem Immunol Allergy 2012; 98:118-41; PMID:22767061; http://dx.doi.org/10.1159/000336505
11. Yang XY, Chen QF, Li YP, Wu SM. Mycobacterium vaccae as adjuvant therapy to anti-tuberculosis chemotherapy in never-treated tuberculosis patients: a metaanalysis. PLoS One 2011; 6:e23826; PMID:21909406; http://dx.doi.org/10.1371/ journal.pone.0023826
12. Luo Y, Lu S, Guo S. Immunotherapeutic effect of Mycobacterium vaccae on multi-drug resistant pulmonary tuberculosis. Zhonghua Jie He He Hu Xi Za Zhi 2000; 23:85-8; PMID:11778496
13. de Bruyn G, Garner P. Mycobacterium vaccae immunotherapy for treating tuberculosis. Cochrane Database Syst Rev 2003; 1:CD001166; PMID:12535403
14. Mwinga A, Nunn A, Ngwira B, Chintu C, Warndorff D, Fine P, et al.; LUSKAR collaboration. Mycobacterium vaccae (SRL172) immunotherapy as an adjunct to standard antituberculosis treatment in HIV-infected adults with pulmonary tuberculosis: a randomised placebo-controlled trial. Lancet 2002; 360:1050-5; PMID:12383985; http://dx.doi.org/10.1016/S0140-6736(02)11141-X
15. Durban Immunotherapy Trial Group. Immunotherapy with Mycobacterium vaccae in patients with newly diagnosed pulmonary tuberculosis: a randomised controlled trial. Lancet 1999; 354:116-9; PMID:10408487; http://dx.doi.org/10. 1016/S0140-6736(98)10448-8
16. Dlugovitzky D, Notario R, Martinel-Lamas D, Fiorenza G, Farroni M, Bogue C, et al. Immunotherapy with oral, heat-killed, Mycobacterium vaccae in patients with moderate to advanced pulmonary tuberculosis. Immunotherapy 2010; 2:159-69; PMID:20635925; http://dx.doi.org/10.2217/imt.09.90
17. Wang W, Jin G, Ye Y, Xia X, Wang A, Zhuang Y, et al. A clinical study on vaccine of Mycobacterium vaccae in treating pulmonary tuberculosis. Zhonghua Jie He He Hu Xi Za Zhi 1999; 22:108-10; PMID:11820954
18. Luo Y; National Cooperation Group On Clinical Study Of Mycobacterium Vaccae Vaccine. The immunotherapeutic effect of Mycobacterium vaccae vaccine on initially treated pulmonary tuberculosis. Zhonghua Jie He He Hu Xi Za Zhi 2001; 24:43-7; PMID:11802939
19. Johnson JL, Kamya RM, Okwera A, Loughlin AM, Nyole S, Hom DL, et al.; The Uganda-Case Western Reserve University Research Collaboration. Randomized controlled trial of Mycobacterium vaccae immunotherapy in non-human immunodeficiency virus-infected Ugandan adults with newly diagnosed pulmonary tuberculosis. J Infect Dis 2000; 181:1304-12; PMID:10753731; http://dx.doi.org/10.1086/315393
20. Bourinbaiar AS, Mezentseva MV, Butov DA, Nyasulu PS, Efremenko YV, Jirathitikal V, et al. Immune approaches in tuberculosis therapy: a brief overview. Expert Rev Anti Infect Ther 2012; 10:381-9; PMID:22397570; http://dx.doi.org/10.1586/eri.12.1
21. Efremenko YV, Arjanova OV, Prihoda ND, Yurchenko LV, Sokolenko NI, Mospan IV, et al. Clinical validation of sublingual formulations of Immunoxel (Dzherelo) as an adjuvant immunotherapy in treatment of TB patients. Immunotherapy 2012; 4:273-82; PMID:22401633; http://dx.doi.org/10.2217/imt.11. 176
22. Butov DA, Efremenko YV, Prihoda ND, Yurchenko LI, Sokolenko NI, Arjanova OV, et al. Adjunct immune therapy of first-diagnosed TB, relapsed TB, treatment-failed TB, multidrug-resistant TB and TB/HIV. Immunotherapy 2012; 4:687-95; PMID:22853755; http://dx.doi.org/10.2217/imt.12.59
23. McConkey B, Situnayake RD. Effects of rifampicin with and without isoniazid in rheumatoid arthritis. J Rheumatol 1988; 15:46-50; PMID:3351840
24. Arjanova OV, Butov DA, Prihoda ND, Zaitzeva SI, Yurchenko LV, Sokolenko NI, et al. One-month immunotherapy trial in treatment-failed TB patients. Open J Immunol 2011; 1:50-5; http://dx.doi.org/10.4236/oji.2011.12006
25. Arjanova OV, Butov DA, Prihoda ND, Zaitzeva SI, Yurchenko LV, Sokolenko NI, et al. Therapeutic vaccination of treatment-failed TB patients on "palliative" support consisting of isoniazid and rifampicin. Mycobact Dis 2012; S1:001.
26. Yang XY, Chen QF, Cui XH, Yu Y, Li YP. Mycobacterium vaccae vaccine to prevent tuberculosis in high risk people: a meta-analysis. J Infect 2010; 60:320-30; PMID:20156481; http://dx.doi.org/10.1016/j.jinf.2010.02.005
27. NIH Policy for Data and Safety Monitoring. NIH Guide Grants Contracts 1998; 12; http://grants.nih.gov/grants/guide/notice-files/not98-084.htm.